SequelSEC

GOLDENWELL BIOTECH, INC. GWLL

Food and Kindred Products · CIK 0001800373 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$55
Fiscal year ended 2025-12-31
Operating income
-$113.33K
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

GOLDENWELL BIOTECH, INC. (GWLL) reported revenue of $55 and net income of -$296.47K for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from GOLDENWELL BIOTECH, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Food and Kindred Products.

Income

GOLDENWELL BIOTECH, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$55$139$1.84K$47.80K$15.97K$0$0
Cost of revenue$43$75$1.17K$22.61K$7.58K$0$0
Gross profit$12$64$666$25.19K$8.39K$0$0
Operating income-$113.33K-$123.10K-$115.83K-$985.10K-$118.27KUnavailableUnavailable
Net income-$296.47K-$131.50K-$117.36K-$985.10K-$116.98K-$6.32K-$2.31K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 99.00Mshares 99.00Mshares 99.00MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailable-$131.50K-$117.36KUnavailable-$118.27K-$6.37K-$2.60K
Income tax expense$0$0$0$0$0$0$0
Diluted EPS$0.00$0.00$0.00UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable$126.66K$6.37K$2.60K
General & administrative$113.34K$123.16K$116.49K$1.01M$126.66KUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

GOLDENWELL BIOTECH, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalentsUnavailableUnavailable$53.23K$46.00K$213.56K$248.57K$246.59K
Total assets$36.12K$224.19K$228.09K$248.40K$460.98K$248.57K$246.59K
Current assetsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$246.59K
Total liabilities$379.83K$271.43K$143.84K$46.78K$159.27K$0$0
Current liabilities$101.86K$1.86KUnavailableUnavailable$159.27K$0$0
Total equity incl. NCI-$343.71K-$47.24K$84.26K$201.62K$301.71K$248.57K$246.59K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$174.74K$174.79K$174.86K$176.06K$198.67K$0Unavailable
Accounts receivableUnavailable$0$0$0$0UnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$173.98K$46.34KUnavailableUnavailableUnavailableUnavailable
Accounts payable$0$0$0$0$111.49K$0Unavailable

Cash flow

GOLDENWELL BIOTECH, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$22.63K-$123.08K-$113.15K-$1.07M-$205.14K-$6.32K-$2.31K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$0$119.25K$120.39K$905.00K$170.12K$8.30K$248.90K
Net change in cashUnavailableUnavailableUnavailableUnavailable-$35.01K$1.98K$246.59K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

GOLDENWELL BIOTECH, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin21.8%46.0%36.3%52.7%52.5%UnavailableUnavailable
Operating margin-206047.3%-88559.7%-6308.6%-2060.9%-740.7%UnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Revenue YoY growth-60.4%-92.4%-96.2%199.4%UnavailableUnavailableUnavailable
Net margin-539038.2%-94602.9%-6392.2%-2060.9%-732.6%UnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GWLL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-K · Filed 2026-07-01View SEC filing
10-Q · Filed 2026-07-01View SEC filing
10-Q/A · Filed 2026-06-29View SEC filing
10-Q/A · Filed 2026-06-26View SEC filing
10-Q/A · Filed 2026-06-26View SEC filing

Companies in the same industry

BGS BOF BRBR BRLS BYND CAG CPB FLO HAIN LSF MDLZ OFRM

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.